Informationen:
Fehler:
ID
34757
Beschreibung
A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c; ODM derived from: https://clinicaltrials.gov/show/NCT01785771
Link
https://clinicaltrials.gov/show/NCT01785771
Stichworte
Versionen (1)
- 27.01.19 27.01.19 -
Rechteinhaber
See clinicaltrials.gov
Hochgeladen am
27. Januar 2019
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Type 2 Diabetes NCT01785771
Eligibility Type 2 Diabetes NCT01785771
- StudyEvent: Eligibility
Ähnliche Modelle
Eligibility Type 2 Diabetes NCT01785771
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Age | Diabetes Mellitus, Non-Insulin-Dependent
Item
men or women age 18 to 80 years with type 2 diabetes
boolean
C0001779 (UMLS CUI [1])
C0011860 (UMLS CUI [2])
C0011860 (UMLS CUI [2])
Diet therapy | Exercise | Combined Modality Therapy | Metformin Dose Stable | Sulfonylurea Dose Stable | Thiazolidinediones Dose Stable
Item
on stable treatment regimen of diet and exercise alone or in combination with a stable & optimal or near-optimal dose of metformin, sulfonylurea, tzd or combination of these drugs
boolean
C0012159 (UMLS CUI [1])
C0015259 (UMLS CUI [2])
C0009429 (UMLS CUI [3])
C0025598 (UMLS CUI [4,1])
C0178602 (UMLS CUI [4,2])
C0205360 (UMLS CUI [4,3])
C0038766 (UMLS CUI [5,1])
C0178602 (UMLS CUI [5,2])
C0205360 (UMLS CUI [5,3])
C1257987 (UMLS CUI [6,1])
C0178602 (UMLS CUI [6,2])
C0205360 (UMLS CUI [6,3])
C0015259 (UMLS CUI [2])
C0009429 (UMLS CUI [3])
C0025598 (UMLS CUI [4,1])
C0178602 (UMLS CUI [4,2])
C0205360 (UMLS CUI [4,3])
C0038766 (UMLS CUI [5,1])
C0178602 (UMLS CUI [5,2])
C0205360 (UMLS CUI [5,3])
C1257987 (UMLS CUI [6,1])
C0178602 (UMLS CUI [6,2])
C0205360 (UMLS CUI [6,3])
Hemoglobin A1c measurement
Item
hba1c >10.0% and ≤12.0%
boolean
C0474680 (UMLS CUI [1])
GLP-1 Receptor Agonist
Item
prior treatment with any glp-1 receptor agonist
boolean
C2917359 (UMLS CUI [1])
Hypersensitivity Exenatide | Hypersensitivity Liraglutide
Item
history of hypersensitivity to exenatide or liraglutide
boolean
C0020517 (UMLS CUI [1,1])
C0167117 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C1456408 (UMLS CUI [2,2])
C0167117 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C1456408 (UMLS CUI [2,2])
Plasma fasting glucose measurement
Item
fpg >300 mg/dl
boolean
C0583513 (UMLS CUI [1])
Medullary carcinoma of thyroid | Multiple Endocrine Neoplasia Type | Family history of multiple endocrine neoplasia Type
Item
history of medullary thyroid cancer or a family or personal history of multiple endocrine neoplasia type 2
boolean
C0238462 (UMLS CUI [1])
C0027662 (UMLS CUI [2,1])
C0332307 (UMLS CUI [2,2])
C4039247 (UMLS CUI [3,1])
C0332307 (UMLS CUI [3,2])
C0027662 (UMLS CUI [2,1])
C0332307 (UMLS CUI [2,2])
C4039247 (UMLS CUI [3,1])
C0332307 (UMLS CUI [3,2])
Dipeptidyl-Peptidase IV Inhibitors | Incretin mimetic product | alpha-Glucosidase Inhibitors | Meglitinide | Insulin
Item
taking dpp-4 inhibitors, incretin mimetics, alpha glucosidase inhibitors, meglitinides or insulin within last 3 months
boolean
C1827106 (UMLS CUI [1])
C1562104 (UMLS CUI [2])
C1299007 (UMLS CUI [3])
C0065880 (UMLS CUI [4])
C0021641 (UMLS CUI [5])
C1562104 (UMLS CUI [2])
C1299007 (UMLS CUI [3])
C0065880 (UMLS CUI [4])
C0021641 (UMLS CUI [5])
Pancreatitis
Item
history of pancreatitis
boolean
C0030305 (UMLS CUI [1])